Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Middleton

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Scientific Reports|May 10, 2018
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinomaT P MacGregor, R Carter, R S Gillies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
ESMO Open|October 12, 2024
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trialE Scanlon, A Lavery, M Albraikat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Scientific Reports|May 10, 2018
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinomaT P MacGregor, R Carter, R S Gillies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
ESMO Open|October 12, 2024
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trialE Scanlon, A Lavery, M Albraikat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 6